Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway

Multiple myeloma (MM) is a hematopoietic malignancy characterized by the clonal proliferation of antibody-secreting plasma cells. Bortezomib (BZM), the first FDA-approved proteasome inhibitor, has significant antimyeloma activity and prolongs the median survival of MM patients. However, MM remains i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yulong, Xu, Li, Wu, Xiaodong, Feng, Juan, Shu, Mimi, Gu, Hongtao, Gao, Guangxun, Zhang, Jinyi, Dong, Baoxia, Chen, Xiequn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848415/
https://www.ncbi.nlm.nih.gov/pubmed/30837032
http://dx.doi.org/10.3727/096504018X15443011011637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848415/
https://www.ncbi.nlm.nih.gov/pubmed/30837032
http://dx.doi.org/10.3727/096504018X15443011011637

Ejemplares similares